116
Participants
Start Date
November 30, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
Tovaxin
2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
Winthrop University Hospital - Clinical Trials Unit, Mineola
Upstate Clinical Research, LLC, Albany
University of Pennsylvania, Philadelphia
Raleigh Neurology Associates, Raleigh
Neurology Consultants of the Carolinas, PA, Charlotte
Medical College of Georgia - Department of Neurology, Augusta
Neurological Associates, Pompano Beach
Bradenton Neurology, Bradenton
North Central Neurology Associates, PC, Cullman
Associates in Neurology, Lexington
Neurological Research Institute, Columbus
Neurology & Neuroscience Associates, Inc., Akron
Neurology Specialists, Inc, Dayton
Allied Physicians Inc, Fort Wayne
St Mary's of Michigan - Field Neuroscience Institute, Saginaw
Consultants in Neurology, Ltd., Northbrook
MidAmerica Neuroscience Institute, Lenexa
The Maxine Mesinger MS Clinic/Baylor College of Medicine, Houston
Integra Clinical Research, LLC, San Antonio
Central Texas Neurology, Round Rock
Patricia A Fodor, PC, Colorado Springs
Xenoscience - 21st Century Neurology, Phoenix
HOPE Research Institute, Phoenix
Alta Bates Summit Medical Center - East Bay Physicians Medical Group, Berkeley
Providence St. Vincent Medical Center - Northwest MS Center, Portland
MS Center at Evergreen, Kirkland
Ayres & Associates Clinical Trials, Lebanon
Lead Sponsor
Opexa Therapeutics, Inc.
INDUSTRY